MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Omeros Company Profile (NASDAQ:OMER)

Consensus Ratings for Omeros (NASDAQ:OMER) (?)
Ratings Breakdown: 9 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $41.71 (295.40% upside)

Analysts' Ratings History for Omeros (NASDAQ:OMER)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016FBR & Co.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016WBB SecuritiesReiterated RatingBuy$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/4/2016Maxim GroupInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Cantor FitzgeraldInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016WedbushReiterated RatingOutperform$62.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016Needham & Company LLCLower Price TargetBuy$30.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2015Roth CapitalReiterated RatingBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/18/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015MLV & Co.Reiterated RatingBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Omeros (NASDAQ:OMER)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116($0.43)($0.54)$8.79 million$7.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q415($0.53)($0.52)$5.35 million$6.66 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.47)($0.46)$7.97 million$3.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.56)($0.44)$2.86 million$3.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.63)($0.51)$0.15 million$0.39 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015Q4($0.62)($0.61)$0.15 million$0.18 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q114($0.59)($0.54)$0.43 million$0.21 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q2($0.56)($0.53)$0.37 million$0.45 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q1($0.45)($0.45)$0.45 million$0.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($0.38)($0.05)$0.17 million$1.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.44)($0.46)$0.14 million$0.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2013Q213($0.38)($0.48)$1.19 million$0.14 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2013Q1 2013($0.39)($0.40)$1.39 million$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2013($0.35)($0.30)$1.49 million$1.58 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312($0.34)($0.51)$1.42 million$1.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2012($0.36)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2011($0.39)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Omeros (NASDAQ:OMER)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.52)($0.42)($0.47)
Q2 20163($0.52)($0.31)($0.43)
Q3 20163($0.47)($0.22)($0.36)
Q4 20163($0.40)($0.12)($0.30)
Q1 20171($0.32)($0.32)($0.32)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171($0.05)($0.05)($0.05)
Q4 20171$0.12$0.12$0.12
(Data provided by Zacks Investment Research)
Dividend History for Omeros (NASDAQ:OMER)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Omeros (NASDAQ:OMER)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/15/2016Marcia S KelbonVPSell15,900$11.42$181,578.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Marcia S KelbonVPSell15,900$9.94$158,046.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016Marcia S KelbonVPSell15,900$15.18$241,362.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2016Thomas J CableDirectorSell2,000$14.81$29,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2015Marcia S. KelbonVPSell15,900$15.00$238,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2015Peter A Md DemopulosDirectorBuy3,962$12.68$50,238.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Thomas J CableDirectorSell2,000$18.78$37,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2015Thomas J CableDirectorSell2,000$24.50$49,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2014Peter A Md DemopulosDirectorBuy6,153$16.20$99,678.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Thomas J CableDirectorSell5,000$11.80$59,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2013Thomas J CableDirectorSell5,000$5.21$26,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2013Thomas J CableDirectorSell5,000$3.98$19,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2013Ray AspiriDirectorBuy40,000$5.72$228,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/3/2013Arnold C HanishDirectorBuy2,000$5.58$11,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Omeros (NASDAQ:OMER)
DateHeadline
06/29/16 08:29 AMCould Omeros Corporation Decline After Today's Huge Increase? - Engelwood Daily
06/29/16 06:00 AMOmeros Corporation Announces Completion of Patient Enrollment in Pediatric Trial of OMIDRIA® - [Business Wire] - Omeros Corporation , a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that it has completed enrollment in the post-marketing pediatric clinical trial that is expected to provide ...
06/28/16 05:36 PMReport delivers insight into the hepatocellular carcinoma pipeline landscape and therapeutics under development ... - WhaTech
06/25/16 09:20 AMOmeros Corporation (OMER) Updated Price Targets - FTSE News
06/24/16 08:12 AMGlobal Hypercholesterolemia Pipeline Report 2016 - Therapeutics Review of 36 Companies & Drug Profile Activity - Research and Markets
06/20/16 07:15 AMOmeros Corporation (OMER) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 05:26 PMGlobal Diabetic Neuropathy Therapeutics Pipeline Review 2016 - Research and Markets
06/15/16 05:35 PMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Omeros (NASDAQ: OMER) and Infinity ... - Markets.co
06/13/16 08:45 AMSeattle biotech outpaces Washington's public companies -
06/10/16 03:17 PMOMEROS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/08/16 06:02 PMOmeros Corporation (NASDAQ:OMER) plummeted -8.01%: Horizon Pharma plc (NASDAQ:HZNP), MannKind Corp ... - KC Register
06/08/16 01:26 PMETF’s with exposure to Omeros Corp. : June 8, 2016 -
06/08/16 08:37 AMHealthcare Losers: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Catalent, Inc. (NYSE:CTLT), CytRx Corporation ... - KC Register
06/06/16 09:18 AMOmeros Corporation (OMER) Broker Price Targets For The Coming Week - Share Trading News
06/05/16 08:20 AMDon’t exterminate the zebra mussels or ruffes
06/03/16 09:38 AMCantor Fitzgerald Starts Omeros With Buy, $21PT - Cantor Fitzgerald has initiated coverage of Omeros Corporation (NASDAQ: OMER) with a Buy rating and $21 price target, saying that "cash flows from its recently launched eye drug OMIDRIA could fuel its pipeline for years to come." OMIDRIA has been approved in the U.S. and Europe for alleviating complications during following eye lens surgery. Seattle, Washington-based Omeros has several clinical and late-stage preclinical programs in development, including complement-mediated disorders, ...Full story available on Benzinga.com
06/03/16 04:51 AMCoverage initiated on Omeros by Cantor Fitzgerald -
06/02/16 06:00 PMCantor Fitzgerald Initiates Coverage on Omeros Co. (OMER) - Let Me Know About This - Cantor Fitzgerald Initiates Coverage on Omeros Co. (OMER)Let Me Know About ThisOmeros logo Equities researchers at Cantor Fitzgerald assumed coverage on shares of Omeros Co. (NASDAQ:OMER) in a note issued to investors on Thursday. The brokerage set a “buy” rating and a $21.00 price target on the biopharmaceutical company's ...Omeros Co. (OMER) Research Coverage Started at Cantor FitzgeraldCommunity Financial Newsall 3 news articles »
06/01/16 08:33 AMType 2 Diabetes Market Pipeline Covering 221 Companies for H1 2016 Reviewed in New Research Report - PR Newswire (press release) - Type 2 Diabetes Market Pipeline Covering 221 Companies for H1 2016 Reviewed in New Research ReportPR Newswire (press release)Companies discussed in this Type 2 Diabetes Pipeline Review, H1 2016 report include Addex Therapeutics Ltd, Adocia, Advinus Therapeutics Ltd., Aegis Therapeutics, LLC, AFFiRiS AG, Alchemia Limited, Alize Pharma SAS, AlphaMab Co., Ltd, Amarantus ... A/S ...and more »
05/31/16 08:37 AMPipeline of Asthma Market Covering 129 Companies Reviewed for H1 2016 in New Research Report - PR Newswire (press release) - Pipeline of Asthma Market Covering 129 Companies Reviewed for H1 2016 in New Research ReportPR Newswire (press release)... Inc., Mitsubishi Tanabe Pharma Corporation, Mycenax Biotech Inc., NAL Pharmaceuticals Ltd., NeoPharm Co., Ltd., Nostrum Pharmaceuticals, LLC, Novartis AG, Omeros Corporation, Ono Pharmaceutical Co., Ltd., OPKO Health, Inc., Orbis Biosciences, Inc., ...and more »
05/31/16 08:37 AMTop Losers: Hercules Offshore, Inc. (NASDAQ:HERO), Terex Corporation (NYSE:TEX), United Fire Group, Inc ... - KC Register - Top Losers: Hercules Offshore, Inc. (NASDAQ:HERO), Terex Corporation (NYSE:TEX), United Fire Group, Inc ...KC RegisterOn 17 May, Omeros Corporation (NASDAQ:OMER) announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC ('Oxford') and East West Bank ('East West') to provide the Company with an additional $20 million in ...
05/27/16 02:46 PM2016 Asthma Pipeline Market Analysis - Mycenax Biotech Inc.,NAL Pharmaceuticals Ltd.,NeoPharm Co., Ltd.,Nostrum Pharmaceuticals, LLC,Novartis AG,Omeros Corporation,Ono Pharmaceutical Co., Ltd.,OPKO Health, Inc.,Orbis Biosciences, Inc.,Orion Oyj,Oxagen Limited,Palatin Technologies, Inc.,Panacea ...
05/24/16 02:43 PMRtw Investments LLC Decreased Stake in Omeros Corp (NASDAQ:OMER) by $13.41 Million as Shares Rose - CCH Daily News - Rtw Investments LLC Decreased Stake in Omeros Corp (NASDAQ:OMER) by $13.41 Million as Shares RoseCCH Daily NewsRtw Investments Llc decreased its stake in Omeros Corp (NASDAQ:OMER) by 50.07% based on its latest 2016Q1 regulatory filing with the SEC. Rtw Investments Llc sold 893,980 shares as the company's stock rose 3.72% with the market. The institutional ...and more »
05/24/16 12:49 PMThe Sub Dollar Stock In The 800 Billion Cigarette Industry The Tobacco Giants Need To Stay Relevant -
05/20/16 11:00 AMETF’s with exposure to Omeros Corp. : May 20, 2016 -
05/19/16 04:18 PMOMEROS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation -
05/19/16 01:22 PMOmeros Corp. :OMER-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 07:42 AMOmeros Announces Debt Financing Transaction for $20 Million in Additional Funds - [at noodls] - SEATTLE--(BUSINESS WIRE)--May 17, 2016-- Omeros Corporation (NASDAQ: OMER) (the 'Company') today announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC ...
05/17/16 07:39 AMBRIEF-Omeros enters debt financing transaction for $20 mln in additional funds - * Entered into an amendment to its existing credit facility to provide company with an additional $20 million in unrestricted cash
05/17/16 06:01 AM7:01 am Omeros amends credit facility to provide for an additional $20 mln in unrestricted cash by funding remaining tranches of facility -
05/15/16 12:58 AMSt Lucia Jazz Festival turns 25 - Trinidad News - St Lucia Jazz Festival turns 25Trinidad NewsWHEN the St Lucia Jazz Festival began in 1991, there were about 100 patrons. However, 25 years later, hundreds of thousands of people attend the annual event and it is one of the staples of the Caribbean music scene. Tracey Warner-Arnold, St Lucia's ...and more »
05/13/16 07:59 PMOmidria reduces cataract surgery time, complications - Healio - Omidria reduces cataract surgery time, complicationsHealioOmidria (phenylephrine 1%/ketorolac 0.3%, Omeros) is the first intracameral FDA-approved medication for routine use in cataract surgery, Rosenberg said. The study included 641 ... disclosures. Co-author Donnenfeld reports he is a consultant for Omeros.
05/12/16 02:52 PMShining Stocks in News Recap- Dermira (NASDAQ:DERM), Broadcom (NASDAQ:AVGO), Omeros (NASDAQ:OMER) - Seneca Globe - Shining Stocks in News Recap- Dermira (NASDAQ:DERM), Broadcom (NASDAQ:AVGO), Omeros (NASDAQ:OMER)Seneca GlobeOmeros Corporation (NASDAQ:OMER) to close at $10.51 by felling -16.32% with session volume was recorded 1.82 Million. Omeros Corporation (OMER) reported a loss of $20.5 million in its first quarter. The Seattle-based firm stated it had a loss of 54 ...and more »
05/12/16 08:54 AMEdited Transcript of OMER earnings conference call or presentation 10-May-16 1:00pm GMT -
05/11/16 08:00 PMBrokers Set Expectations for Omeros Co.'s Q1 2017 Earnings (OMER) - Washington News Wire - Washington News WireBrokers Set Expectations for Omeros Co.'s Q1 2017 Earnings (OMER)Washington News WireOmeros logo Omeros Co. (NASDAQ:OMER) – Investment analysts at Wedbush issued their Q1 2017 earnings per share estimates for Omeros in a research report issued on Tuesday, according to Zacks Investment Research. Wedbush analyst L. Moussatos ...Omeros Co. (OMER) Stock Price Down 14.3% on Disappointing EarningsNewsWay 21Omeros Co. (OMER) Stock Price Down 14.3% Following Weak EarningsWeb Breaking NewsLeonard M. Blum Joins Omeros to Lead Business and Commercial ActivitiesBusiness Wire (press release)Wall Street 24 -The Postall 26 news articles »
05/10/16 02:49 PMStocks in News: Nuance Communications, Inc. (NASDAQ:NUAN), Omeros Corporation (NASDAQ:OMER), Macy's, Inc ... - KC Register - Stocks in News: Nuance Communications, Inc. (NASDAQ:NUAN), Omeros Corporation (NASDAQ:OMER), Macy's, Inc ...KC RegisterOmeros Corporation (NASDAQ:OMER) announced that new research related to the clinical utility of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% and the importance of preempting intraoperative miosis and inflammation during cataract surgery ...and more »
05/10/16 08:00 AMOmeros Corp Earnings Call scheduled for 9:00 am ET today -
05/10/16 06:48 AMOmeros Corporation Reports First Quarter 2016 Financial Results - [at noodls] - -- Conference Call Today at 9:00 a.m. ET -- SEATTLE--(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing ...
05/10/16 06:32 AMOMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/10/16 06:28 AMOmeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA® - [at noodls] - -- Initiates International Market Expansion -- SEATTLE--(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing ...
05/10/16 06:28 AMLeonard M. Blum Joins Omeros to Lead Business and Commercial Activities - [at noodls] - SEATTLE--(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics ...
05/10/16 06:26 AMOmeros reports 1Q loss -
05/10/16 06:23 AMOMEROS CORP Files SEC form 10-Q, Quarterly Report -
05/10/16 06:07 AMQ1 2016 Omeros Corp Earnings Release - Before Market Open -
05/08/16 02:51 PMNext Weeks Broker Price Targets For Omeros Corporation (OMER) - Share Trading News - Next Weeks Broker Price Targets For Omeros Corporation (OMER)Share Trading News08/11/2015 – Omeros Corporation had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 38 price target on the stock. 05/12/2015 – Omeros Corporation was upgraded to “hold” by analysts at Zacks. Omeros Corporation has a 50 day ...and more »
05/06/16 04:29 PMIs This The Reason That Omeros Corporation Fell 17.7% in April? - News that the company is looking to raise capital from a share offering sends shares lower.
05/05/16 02:53 PMEsophageal Cancer Pipeline H1 2016 Market Report on 54 Companies - PR Newswire (press release) - Esophageal Cancer Pipeline H1 2016 Market Report on 54 CompaniesPR Newswire (press release)... Inc., Komipharm International Co., Ltd., MacroGenics, Inc., Mebiopharm Co., Ltd., MedImmune, LLC, Merck & Co., Inc., Novartis AG, Omeros Corporation, Omnitura Therapeutics Inc., Oncolys BioPharma Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc ...and more »
05/05/16 01:03 AMEsophageal Cancer Pipeline H1 2016 Market Report On 54 Companies - Merck & Co., Inc., Novartis AG, Omeros Corporation, Omnitura Therapeutics Inc., Oncolys BioPharma Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Proteo, Inc., Puma Biotechnology, Inc., Shenzen SiBiono GeneTech Co., Ltd., Shionogi & Co., Ltd., Sihuan ...
05/04/16 06:20 AMOmeros Corporation to Announce First Quarter 2016 Financial Results on May 10, 2016 - [at noodls] - SEATTLE--(BUSINESS WIRE)--May 4, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics ...
04/28/16 02:52 PMBroker Roundup For Omeros Corporation (OMER) - Share Trading News - Broker Roundup For Omeros Corporation (OMER)Share Trading News08/11/2015 – Omeros Corporation had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 38 price target on the stock. 05/12/2015 – Omeros Corporation was upgraded to “hold” by analysts at Zacks. The share price of Omeros ...and more »
About Omeros

Omeros logoOmeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL), which is replacement surgery, to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is derived from its PharmacoSurgery platform, which is for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. It also has six clinical-stage development programs in its pipeline, which includes a group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor, drug targets and the other used to generate antibodies.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: OMER
  • CUSIP: 68214310
Key Metrics:
  • Previous Close: $10.55
  • 50 Day Moving Average: $10.92
  • 200 Day Moving Average: $12.49
  • P/E Ratio: N/A
  • P/E Growth: -0.06
  • Market Cap: $412.87M
  • Current Quarter EPS Consensus Estimate: $-1.76 EPS
Additional Links:
Omeros (NASDAQ:OMER) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha